HomeBoceprevirBoceprevir + Abacavir Sulfate Dolutegravir Sodium Lamivudine

Does Boceprevir Interact with Abacavir Sulfate Dolutegravir Sodium Lamivudine?

Boceprevir and Abacavir Sulfate Dolutegravir Sodium Lamivudine have a unknown drug interaction according to U.S. FDA drug labeling data. Using cross-study comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir. Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Unknown
Abacavir Sulfate Dolutegravir Sodium Lamivudine Class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Management
Consult your pharmacist
Data Source
U.S. FDA via OpenFDA

What To Tell Your Doctor or Pharmacist

If you are taking Boceprevir and your doctor is considering prescribing Abacavir Sulfate Dolutegravir Sodium Lamivudine (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Never stop or change either medication without first consulting your healthcare provider
💊 Boceprevir+💊 Abacavir Sulfate Dolutegravir Sodium Lamivudine(Triumeq)

Severity & Interaction Details

ℹ️
unknown
Interaction documented — severity unclassified
The FDA label notes an interaction but the severity is not classified in our dataset.
Severity scale
MinorContra
On record
Yes
Drug A class
Drug B class
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor
Source
FDA drug label - abacavir sulfate, dolutegravir sodium, lamivudine

What this means in plain English

Using cross-study comparisons to historical pharmacokinetic data for each interacting drug, dolutegravir did not appear to affect the pharmacokinetics of the following drugs: atazanavir, darunavir, efavirenz, etravirine, fosamprenavir, lopinavir, ritonavir, and boceprevir. Darunavir/ritonavir, lopinavir/ritonavir, rilpivirine, tenofovir, boceprevir, prednisone, rifabutin, and omeprazole had no clinically significant effect on the pharmacokinetics of dolutegravir.

About Boceprevir and Abacavir Sulfate Dolutegravir Sodium Lamivudine

Abacavir Sulfate Dolutegravir Sodium Lamivudine is a Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor. Abacavir Sulfate Dolutegravir Sodium Lamivudine is also sold under the brand name Triumeq. Abacavir Sulfate Dolutegravir Sodium Lamivudine is taken by mouth. Abacavir Sulfate Dolutegravir Sodium Lamivudine additionally carries an FDA boxed warning, the FDA's strongest safety alert.

Recent research & FDA safety updates

Live

Auto-aggregated from PubMed E-utilities and FDA safety data.

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Boceprevir and Abacavir Sulfate Dolutegravir Sodium Lamivudine against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →
Data integrity: Every interaction shown is extracted directly from official U.S. FDA drug labeling via openFDA and the U.S. National Library of Medicine (NIH) — no interactions are invented, inferred, or manually edited. Maintained by CheckDrugInteractions.com. See our methodology or report a correction at support@checkdruginteractions.com.

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine, supplemented with a small number of well-established interactions from curated clinical references. For informational purposes only. Always consult your pharmacist or physician.